ABSTRACT - 592694 The disclosure relates to a compound represented by structural formula shown herein and pharmaceutically acceptable compositions thereof, which are useful as modulators of ATP-Binding Cassette (ABC) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), and are suitable for treating a condition, disease, or disorder selected from cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, lipid processing deficiencies, lysosomal storage diseases, neurodegenerative diseases, polyglutamine neurological disorders, spongiform encephalopathies, chronic obstructive pulmonary disease (COPD), dry-eye disease, and Sjögrens disease.
